Background: The number of people affected by Huntington’s disease (HD) is far greater than those with manifest HD because it also includes those at risk, both HD gene mutation carriers and family members not carrying the HD mutation. Many relevant needs of young adults from HD families may not be met at present. This includes advice on important life decisions e.g. family planning and having children, psychological support and treatment of medical conditions.
Objective: To survey the opinion of young adults from HD families about relevance and availability of information and support regarding several aspects of HD.
Methods: An online anonymous questionnaire translated into ten languages contained questions regarding the importance and availability of information and support about HD related topics, and attitudes towards research. Answers were captured in categories or on Likert scales.
Results: Information about HD related topics and the availability of peer and professional support are very important for young adults from HD families. In addition, with the exception of general information about HD, or predictive testing, the vast majority of respondents stated that they did not receive enough information on other important topics, for instance regarding legal advice and they did not feel supported enough by healthcare professionals. HD research was considered to be of high value, though most did not participate in HD research.
Conclusion: The results of this survey can help devise a strategy to address these unmet needs and also to facilitate research participation of more young adults from HD families.
RossCA, TabriziSJ. Huntington’s disease: From molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83–98.
2.
VamosM, HambridgeJ, EdwardsM, ConaghanJ. The impact of Huntington’s disease on family life. Psychosomatics. 2007;48(5):400–4.
3.
Forrest KeenanK, MiedzybrodzkaZ, van TeijlingenE, McKeeL, SimpsonSA. Young people’s experiences of growing up in a family affected by Huntington’s disease. Clin Genet. 2007;71(2):120–9.
4.
TeamRC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.
5.
HannanAJ. Environmental enrichment and brain repair: Harnessing the therapeutic effects of cognitive stimulation and physical activity to enhance experience-dependent plasticity. Neuropathol Appl Neurobiol. 2014;40(1):13–25.
6.
EstruchR, RosE, Salas-SalvadoJ, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279–90.
7.
Huntington Study Group. A randomized placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57(3):397–404.
8.
FerreiraJJ, RosserA, CraufurdD, SquitieriF, MallardN, LandwehrmeyerB. Ethyl-eicosapentaenoic acid treatment in Huntington’s disease: A placebo-controlled clinical trial. Mov Disord. 2015;30(10):1426–9.
9.
TrembathMK, HortonZA, TippettL, et al. A retrospective study of the impact of lifestyle on age at onset of Huntington disease. Mov Disord. 2010;25(10):1444–50.
10.
SchnohrP, O’KeefeJH, MarottJL, LangeP, JensenGB. Dose of jogging and long-term mortality: The Copenhagen City Heart Study. J Am Coll Cardiol. 2015;65(5):411–9.
11.
MacLeodR, TibbenA, FrontaliM, et al. Recommendations for the predictive genetic test in Huntington’s disease. Clin Genet. 2013;83(3):221–31.
12.
HelliwellJ, LayardR, SachsJ. World Happiness Report. Columbia University Earth Institute2015.
13.
Munoz-SanjuanI. Support communities involved in disease studies. Nature. 2016;531(7593):141.
14.
CreightonS, AlmqvistEW, MacGregorD, et al. Predictive, pre-natal and diagnostic genetic testing for Huntington’s disease: The experience in Canada from 1987 to 2000. Clin Genet. 2003;63(6):462–75.
15.
WildEJ, TabriziSJ. Targets for future clinical trials in Huntington’s disease: What’s in the pipeline?Mov Disord2014;29(11):1434–45.
16.
PaulsenJS, LongJD, RossCA, et al. Prediction of manifest Huntington’s disease with clinical and imaging measures: A prospective observational study. Lancet Neurol. 2014;13(12):1193–201.
17.
TabriziSJ, ScahillRI, OwenG, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: Analysis of 36-month observational data. Lancet Neurol. 2013;12(7):637–49.
